Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006)
Aim. To investigate the effects of a atorvastatin (Atoris, KRKA) on major clinical parameters in patients with high cardiovascular risk – the participants of the OSCAR Study (2006). Material and methods. The total number of high-risk patients was 930 (472 men). The mean age was 57,8 years. Coronary...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2145 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689297032052736 |
|---|---|
| author | S. A. Shalnova A. D. Deev N. V. Kiseleva |
| author_facet | S. A. Shalnova A. D. Deev N. V. Kiseleva |
| author_sort | S. A. Shalnova |
| collection | DOAJ |
| description | Aim. To investigate the effects of a atorvastatin (Atoris, KRKA) on major clinical parameters in patients with high cardiovascular risk – the participants of the OSCAR Study (2006). Material and methods. The total number of high-risk patients was 930 (472 men). The mean age was 57,8 years. Coronary heart disease (CHD) was diagnosed in 80,1% of men and 70,0% of women. All participants were divided into three groups by their CHD status: no CHD; with uncomplicated CHD; with CHD complications (myocardial infarction, stroke, and revascularisation in anamnesis). In all patients, the levels of risk factors, lipid profile, anthropometric and hemodynamic parameters were assessed. A generic atorvastatin was administered in a fixed start dose of 10-20 mg/d. The duration of the study was approximately 1,5 months. Results. After 8 weeks of Atoris treatment, a significant improvement in hemodynamic and lipid parameters was observed. In patients with CHD complications, lipid profile dynamics was less manifested, but the prevalence of target lipid level achievement was higher, since these individuals started with higher doses of atorvastatin. The total risk of fatal cardiovascular events reduced significantly. Atorvastatin was well-tolerated. Conclusion. Atorvastatin (Atoris, KRKA) is effective and safe in real-world clinical practice. It reduces the risk of cardiovascular events and mortality, also improving quality of life in high-risk patients. |
| format | Article |
| id | doaj-art-3cc229147f5f460d87653696ea43765c |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2010-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-3cc229147f5f460d87653696ea43765c2025-08-20T03:21:40Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-12-019657621854Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006)S. A. Shalnova0A. D. Deev1N. V. Kiseleva2Russian Cardiology Scientific and Clinical ComplexState Research Centre for Preventive Medicine. MoscowState Research Centre for Preventive Medicine. MoscowAim. To investigate the effects of a atorvastatin (Atoris, KRKA) on major clinical parameters in patients with high cardiovascular risk – the participants of the OSCAR Study (2006). Material and methods. The total number of high-risk patients was 930 (472 men). The mean age was 57,8 years. Coronary heart disease (CHD) was diagnosed in 80,1% of men and 70,0% of women. All participants were divided into three groups by their CHD status: no CHD; with uncomplicated CHD; with CHD complications (myocardial infarction, stroke, and revascularisation in anamnesis). In all patients, the levels of risk factors, lipid profile, anthropometric and hemodynamic parameters were assessed. A generic atorvastatin was administered in a fixed start dose of 10-20 mg/d. The duration of the study was approximately 1,5 months. Results. After 8 weeks of Atoris treatment, a significant improvement in hemodynamic and lipid parameters was observed. In patients with CHD complications, lipid profile dynamics was less manifested, but the prevalence of target lipid level achievement was higher, since these individuals started with higher doses of atorvastatin. The total risk of fatal cardiovascular events reduced significantly. Atorvastatin was well-tolerated. Conclusion. Atorvastatin (Atoris, KRKA) is effective and safe in real-world clinical practice. It reduces the risk of cardiovascular events and mortality, also improving quality of life in high-risk patients.https://cardiovascular.elpub.ru/jour/article/view/2145high-risk patientslipid metabolismstatinsoscar study |
| spellingShingle | S. A. Shalnova A. D. Deev N. V. Kiseleva Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) Кардиоваскулярная терапия и профилактика high-risk patients lipid metabolism statins oscar study |
| title | Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) |
| title_full | Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) |
| title_fullStr | Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) |
| title_full_unstemmed | Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) |
| title_short | Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006) |
| title_sort | atorvastatin effectiveness and safety in patients with high cardiovascular risk revising the results of the oscar study 2006 |
| topic | high-risk patients lipid metabolism statins oscar study |
| url | https://cardiovascular.elpub.ru/jour/article/view/2145 |
| work_keys_str_mv | AT sashalnova atorvastatineffectivenessandsafetyinpatientswithhighcardiovascularriskrevisingtheresultsoftheoscarstudy2006 AT addeev atorvastatineffectivenessandsafetyinpatientswithhighcardiovascularriskrevisingtheresultsoftheoscarstudy2006 AT nvkiseleva atorvastatineffectivenessandsafetyinpatientswithhighcardiovascularriskrevisingtheresultsoftheoscarstudy2006 |